Acquisition of the GMP biologics manufacturing facility expands Xcellon’s integrated capabilities from discovery through clinical supply and strengthens U.S. biomanufacturing BELTSVILLE, Md., Aug. 10, 2026 (GLOBE NEWSWIRE) — Xcellon Biologics, a U.S.-based Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, today announced that it has signed a definitive agreement to acquire the GMP biologics manufacturing facility from NextCure, Inc. The acquisition marks a transformational milestone in the company’s evolution, establishing Xcellon as an end-to-end CRDMO with integrated capabilities spanning discovery through clinical supply. As part of its next phase of growth, Xcellon Biologics appointed co-founder Abhishake Chhibber as Chief Executive Officer to lead the...

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 31 July 2026 227,283 648.25 147,336,607    Monday, 3 August 2026 3,000 622.83 1,868,502    Tuesday, 4 August 2026 3,000 618.73 1,856,183    Wednesday, 5 August 2026 3,000 616.55 1,849,658    Thursday, 6 August 2026 3,000 616.67 1,850,019    Friday,...

The transaction is expected to add 12 practice locations and 48 doctors in North Carolina MINNEAPOLIS, Aug. 10, 2026 (GLOBE NEWSWIRE) — Park Dental Partners, Inc. (NASDAQ: PARK). (the “Company”), a leading dental resource organization, today announced that it has entered into a definitive agreement to acquire Village Family Dental DSO. The Village Family Dental DSO is currently affiliated with Village Family Dental practices, a multi-specialty dental group based in Fayetteville, North Carolina. Upon completion, the transaction would mark Park Dental Partners’ expansion into its fourth state and further strengthen its growing presence among premier national dental group practices. Strategic RationaleThe transaction reflects a strong cultural alignment and a shared focus on long-term patient outcomes. It’s expected to:Bring...

NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) — INNOVATE CORP.® (NYSE: VATE) (“INNOVATE”) announced today that it has entered into a Transaction Agreement (the “Agreement”) pursuant to which IES Holdings, Inc. (Nasdaq: IESC) (“IES”) will acquire DBM Global, Inc. (“DBMG”) for cash and stock consideration valued at $650 million (the “Transaction”). INNOVATE, through DBM Global Intermediate Holdco Inc., currently owns approximately 91.21% of the outstanding common stock of DBMG. “This transaction represents a meaningful step in our ongoing efforts to strengthen INNOVATE’s balance sheet and improve our capital structure,” said Paul Voigt, Interim CEO of INNOVATE. “DBMG has a proven track record of strong financial performance, and we are proud of the value created through our partnership over the years. We want to thank Rustin Roach and...

Transaction Establishes New Structural Line of Business, Adding One of the Largest Independent Structural Steel Fabrication and Erection Platforms in the U.S. HOUSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) — IES Holdings, Inc. (“IES”) (NASDAQ: IESC) today announced that it has entered into a definitive agreement to acquire DBM Global Inc. (“DBM Global”), a vertically integrated structural steel fabrication, erection and industrial services platform, from INNOVATE Corp. (“INNOVATE”) (NYSE: VATE) (the “Transaction”). The consideration for DBM Global, including minority interests, is approximately $650 million, comprised of cash and shares of IES common stock. IES expects to fund the cash portion of the consideration through a combination of cash on hand and borrowings under an expanded credit facility being arranged by Wells Fargo. DBM...

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization  Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s BRIDGEWATER, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The combination establishes one of the industry’s few fully integrated biosimilars platforms. “The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company,” said Chirag Patel, Co-Founder and Co-Chief Executive...

Planned Transaction Strengthens Statewide Market Access Through Expanded Pipeline and Storage Infrastructure LONG BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) — California Resources Corporation (NYSE: CRC) today announced an agreement to acquire Crimson Midstream Holdings, LLC (“Crimson”) from CorEnergy Infrastructure Trust, Inc. for total cash consideration of $63 million, subject to certain customary adjustments. Supplemental slides with additional details have been posted to CRC’s website at www.crc.com. “This transaction further strengthens CRC’s position as California’s leading integrated infrastructure energy platform,” said Francisco Leon, President and Chief Executive Officer of CRC. “This diversified midstream network will enhance our ability to efficiently deliver California-produced barrels directly to the highest-value...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use...

Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast and gastric cancersBOSTON and LIEGE, Belgium, Aug. 10, 2026 (GLOBE NEWSWIRE) — Curium™ a leading global radiopharmaceutical company, announced that it has completed the acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company developing innovative diagnostic imaging agents for oncology. Through the transaction, Curium has acquired the global rights to develop, manufacture and commercialize ABS-011, an investigational gallium-68-labeled positron emission tomography (PET) radiodiagnostic tracer designed to target human epidermal growth factor receptor 2 (HER2). HER2 is an important...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use...